Qualigen Therapeutics (QLGN) Competitors $0.10 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends QLGN vs. BCDA, LIXT, IMCC, ONCT, CPHI, GHSI, NCNA, FRTX, PPBT, and SNPXShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include BioCardia (BCDA), Lixte Biotechnology (LIXT), IM Cannabis (IMCC), Oncternal Therapeutics (ONCT), China Pharma (CPHI), Guardion Health Sciences (GHSI), NuCana (NCNA), Fresh Tracks Therapeutics (FRTX), Purple Biotech (PPBT), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. BioCardia Lixte Biotechnology IM Cannabis Oncternal Therapeutics China Pharma Guardion Health Sciences NuCana Fresh Tracks Therapeutics Purple Biotech Synaptogenix BioCardia (NASDAQ:BCDA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Which has preferable valuation & earnings, BCDA or QLGN? BioCardia has higher earnings, but lower revenue than Qualigen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$480K10.56-$11.57M-$5.38-0.44Qualigen Therapeutics$4.98M0.24-$13.42MN/AN/A Does the MarketBeat Community prefer BCDA or QLGN? BioCardia received 7 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 56.00% of users gave BioCardia an outperform vote. CompanyUnderperformOutperformBioCardiaOutperform Votes1456.00% Underperform Votes1144.00% Qualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Is BCDA or QLGN more profitable? Qualigen Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. Company Net Margins Return on Equity Return on Assets BioCardia-1,999.77% N/A -278.27% Qualigen Therapeutics N/A N/A -361.85% Do insiders & institutionals believe in BCDA or QLGN? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate BCDA or QLGN? BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 946.03%. Given BioCardia's higher probable upside, research analysts plainly believe BioCardia is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media prefer BCDA or QLGN? In the previous week, BioCardia had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 5 mentions for BioCardia and 3 mentions for Qualigen Therapeutics. BioCardia's average media sentiment score of 0.00 beat Qualigen Therapeutics' score of -0.53 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has more risk and volatility, BCDA or QLGN? BioCardia has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.74, suggesting that its stock price is 174% less volatile than the S&P 500. SummaryBioCardia beats Qualigen Therapeutics on 11 of the 14 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.47113.8115.12Price / Sales0.24381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book-0.245.324.665.02Net Income-$13.42M$153.56M$119.06M$225.46M7 Day PerformanceN/A0.12%0.79%0.37%1 Month PerformanceN/A15.23%5.65%3.57%1 Year PerformanceN/A41.16%36.76%29.42% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$0.10flatN/A-86.8%$1.21M$4.98M0.0050Stock SplitNews CoverageBCDABioCardia3.1464 of 5 stars$2.33flat$25.00+973.0%-57.9%$4.94M$480,000.00-0.4316News CoverageLIXTLixte Biotechnology0.5954 of 5 stars$2.10-0.5%N/A-25.5%$4.73MN/A-1.183Positive NewsIMCCIM Cannabis0.3972 of 5 stars$2.08flatN/A-29.1%$4.64M$36.15M-0.54340ONCTOncternal Therapeutics2.479 of 5 stars$1.53+4.7%$20.00+1,207.9%-76.2%$4.53M$790,000.00-0.1330CPHIChina PharmaN/A$0.26+1.2%N/A-45.2%$4.49M$7.01M0.00250Analyst ForecastNews CoverageGHSIGuardion Health Sciences1.6481 of 5 stars$3.22-2.1%N/A-47.7%$4.35M$12.25M0.6610Gap DownNCNANuCana3.0979 of 5 stars$1.63+0.6%$25.00+1,433.7%-86.9%$4.30MN/A-0.1330Positive NewsFRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-21.3%$4.30M$8.01M-0.5120PPBTPurple Biotech2.135 of 5 stars$3.19-0.6%$200.00+6,169.6%N/A$4.24MN/A-0.2520News CoverageSNPXSynaptogenix1.7637 of 5 stars$3.04+2.0%$14.00+360.5%-58.7%$4.13MN/A0.004Negative News Related Companies and Tools Related Companies BCDA Competitors LIXT Competitors IMCC Competitors ONCT Competitors CPHI Competitors GHSI Competitors NCNA Competitors FRTX Competitors PPBT Competitors SNPX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QLGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
